374 filings
Page 10 of 19
8-K
08j1z7yy renlmx
25 Apr 13
Bristol-Myers Squibb Reports First Quarter 2013 Financial Results
12:00am
8-K
qt49g63bdo 2d2qubt
8 Apr 13
Departure of Directors or Certain Officers
12:00am
8-K
tthsl
8 Mar 13
Departure of Directors or Certain Officers
12:00am
8-K
gdslo
25 Jan 13
Departure of Directors or Certain Officers
12:00am
8-K
1tumq8 bbwv9nr
24 Jan 13
Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2012 Financial Results
12:00am
8-K
hp04sdqhp 52qb
24 Oct 12
Bristol-Myers Squibb Reports Third Quarter 2012 Financial Results
12:00am
8-K
wl4u19iy
3 Oct 12
Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement
12:00am
8-K
k1wgx8oqcouo045t8
24 Aug 12
Bristol-Myers Squibb Discontinues Development of BMS-986094, an Investigational NS5B Nucleotide for the Treatment of Hepatitis C
12:00am
8-K
e3u0w 7fp3vsoyz4hroq
10 Aug 12
Completion of Acquisition or Disposition of Assets
12:00am
8-K
ot54uahdbj6j0tu
3 Aug 12
Bristol-Myers Squibb Suspends Administration of Study Drug in Clinical Trial of Investigational NS5B Nucleotide for the Treatment of Hepatitis C
12:00am
8-K
xmlpe0hu xfh
31 Jul 12
Entry into a Material Definitive Agreement
12:00am
8-K
orr7v5x ujk
25 Jul 12
Planned Acquisition of Amylin Expected to Add Two Marketed GLP-1 Agonists to Our Diabetes Franchise and Our Alliance with AstraZeneca
12:00am
8-K
lmcw9kpp
3 Jul 12
Entry into a Material Definitive Agreement
12:00am
8-K
x0bkt
7 May 12
Departure of Directors or Certain Officers
12:00am
8-K
n77b4lc0os48ue ku
26 Apr 12
Bristol-Myers Squibb Delivers a Solid First Quarter with Strong Operating Results and Key R&D Milestones
12:00am
8-K
wsbt wnrpo
8 Mar 12
Other Events
12:00am
8-K
cejaelsldzfom
13 Feb 12
Other Events
12:00am
8-K
efcdrytn1ew 0tj
26 Jan 12
Net Sales Rise 7% to $5.5 Billion in Fourth Quarter
12:00am
8-K
v2hiy
24 Jan 12
Bristol-Myers Squibb Names Gerald L. Storch to Board of Directors
12:00am
8-K
w8fuozrctcyxr bjb1
9 Jan 12
Bristol-Myers Squibb to Acquire Inhibitex
12:00am